Fantastic new AHA statement on Triglycerides available for free download at AHA Circulation web site. A must read for all NLA members

 

Circulation 2011 [doi:10.1161/ CIR.0b013e3182160726]).

Go over to my Lipidaholics Anonymous group to learn abut the expert panel on HDL Nomenclature as it applies to a real world case.

The AHA has posted a 2011 update to the AHA Women's Guideline series (last update was 2007 and original set was 2004). Go over to the Lipidaholics Anonymous Group and see how well the new recommendations apply to a real world case.

Venture over to my Lipidaholics group for another pretty deep discussion on the importance of TG-rich lipoproteins. Tragically the discussion was stimuated by a frustrated PhRMA rep trying to deal with a cardiologist who cannot justify drug therapy for elevated triglycerides. As usual I take no prisoners!

 

Tom D

Please go over to my groups page and click on Lipidaholics Anonymous to see a case discussion where a lipidologist and his nurese practitioner analyzed the same case - see who suggested what and then read my comments as I analyzed their statements.

 

TD

Please head over to my Lipidaholic Anonymous Groups Page and check out cases 267 and 268. The first deals with many aspects of hormone therapy in a woman with cardiovascular risk and the other (268) addresses whether niacin should ever be a first line therapy instead of a statin. Feel free to leave a comment.

 

Merry Christmas to all ,  Tom D

Please go over to my Lipid Geeks Group and see a discussion of the seemingly spectacular results seen in the DEFINE trial using the CETP inhinbitor anacetrapib. 

 

Playing the devil's advocate, I raise the following question: in HATS, using simvastatin and high dose niacin vs placebo (unfortunately not vs statin monotherapy) did demonstrate lots of event reduction and plaque benefit in a very short time in much smaller, tiny, tiny study (28 pts on  niacin and simva). Since anacetrapib + statin blew away what niacin plus statin did to lipids and lipoproteins in HATS, should not there have been a statistically significant event reduction even though it was not empowered to show that? If raising HDL-C and apoA-I and blowing away LDL-C, non-HDL-C, apoB and Lp(a) is what matters why no statistically significant event reduction in DEFINE?  What the heck is going on?

 

Please join in the discussion

 

Tom D

Go over to my Lipidaholics Anonymous Group page - join our group - and then read the latest case - a not uncommon problem about tackling Lp(a) issues in the face of a normal lipid panel. Pleas epost comments